• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球从三价口服脊髓灰质炎疫苗(tOPV)向二价口服脊髓灰质炎疫苗(bOPV)的转换:来自南南区域(尼日利亚)的事实、经验与教训,2016年4月

The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV): facts, experiences and lessons learned from the south-south zone; Nigeria, April 2016.

作者信息

Bassey Bassey Enya, Braka Fiona, Vaz Rui Gama, Komakech William, Maleghemi Sylvester Toritseju, Koko Richard, Igbu Thompson, Ireye Faith, Agwai Sylvester, Akpan Godwin Ubong, Tegegne Sisay Gashu, Mohammed Abdul-Aziz Garba, Okocha-Ejeko Angela

机构信息

World Health organization (WHO) Nigeria Country office, UN House, plot 617/618, Diplomatic Drive, Central Business District, Abuja, Garki, PMB 2861, Nigeria.

出版信息

BMC Infect Dis. 2018 Jan 27;18(1):57. doi: 10.1186/s12879-018-2963-6.

DOI:10.1186/s12879-018-2963-6
PMID:29374467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5787308/
Abstract

BACKGROUND

The globally synchronized switch from trivalent Oral Polio Vaccine (tOPV) to bivalent Oral Polio Vaccine (bOPV) took place in Nigeria on April 18th 2016. The country is divided into six geopolitical zones. This study reports the experiences and lessons learned from the switch process in the six states that make up Nigeria's south-south geopolitical zone.

METHODS

This was a descriptive retrospective review of Nigeria's switch plan and structures used for implementing the tOPV-bOPV switch in the south-south zone. Nigeria's National Polio Emergency Operation Centre (NPEOC) protocols, global guidelines and reports from switch supervisors during the switch were used to provide background information for this study. Quantitative data were derived from reviewing switch monitoring and validation documents as submitted to the NPEOC RESULTS: The switch process took place in all 3078 Health Facilities (HFs) and 123 Local Government Areas (LGAs) that make up the six states in the zone. A total of $139,430 was used for this process. The 'healthcare personnel' component received the highest budgetary allocation (59%) followed by the 'logistics' component (18%). Akwa Ibom state was allocated the highest number of healthcare personnel and hence received the most budgetary allocation compared to the six states (total healthcare personnel = 458, total budgetary allocation = $17,428). Validation of the switch process revealed that eight HFs in Bayelsa, Cross-River, Edo and Rivers states still possessed tOPV in cold-chain while six HFs in Cross-River and Rivers states had tOPV out of cold-chain but without the 'do not use' sticker. Akwa-Ibom was the only state in the zone to have bOPV and Inactivated Polio Vaccine (IPV) available in all its HFs monitored.

CONCLUSION

The Nigerian tOPV-bOPV switch was successful. For future Oral Polio Vaccine (OPV) withdrawals, implementation of the switch plan would be more feasible with an earlier dissemination of funds from global donor organizations, which would greatly aid timely planning and preparations. Increased budgetary allocation to the 'logistics' component to accommodate unexpected hikes in transportation prices and the general inefficiencies with power supply in the country is also advised.

摘要

背景

2016年4月18日,尼日利亚全球同步从三价口服脊髓灰质炎疫苗(tOPV)转换为二价口服脊髓灰质炎疫苗(bOPV)。该国分为六个地缘政治区。本研究报告了尼日利亚南南地缘政治区六个州在转换过程中的经验和教训。

方法

这是对尼日利亚南南地区用于实施tOPV - bOPV转换的计划和结构的描述性回顾。尼日利亚国家脊髓灰质炎应急行动中心(NPEOC)的方案、全球指南以及转换期间转换监督员的报告被用于为本研究提供背景信息。定量数据来自对提交给NPEOC的转换监测和验证文件的审查。结果:转换过程在该地区六个州的所有3078个卫生设施(HFs)和123个地方政府区域(LGAs)中进行。此过程总共花费了139,430美元。“医护人员”部分获得的预算分配最高(59%),其次是“后勤”部分(18%)。与六个州相比,阿夸伊博姆州分配的医护人员数量最多,因此获得的预算分配也最多(医护人员总数 = 458人,预算分配总额 = 17,428美元)。转换过程的验证显示,巴耶尔萨州、克罗斯河州、江户州和河流州的8个卫生设施在冷链中仍存有tOPV,而克罗斯河州和河流州的6个卫生设施的tOPV不在冷链中,但没有“请勿使用”标签。阿夸伊博姆州是该地区唯一在所监测的所有卫生设施中都有bOPV和灭活脊髓灰质炎疫苗(IPV)的州。

结论

尼日利亚的tOPV - bOPV转换取得成功。对于未来的口服脊髓灰质炎疫苗(OPV)停用,全球捐助组织更早地发放资金将使转换计划的实施更可行,这将极大地有助于及时规划和准备工作。还建议增加对“后勤”部分的预算分配,以应对运输价格意外上涨以及该国电力供应普遍低效的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09b5/5787308/a7368f35567c/12879_2018_2963_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09b5/5787308/a6486519961c/12879_2018_2963_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09b5/5787308/a7368f35567c/12879_2018_2963_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09b5/5787308/a6486519961c/12879_2018_2963_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09b5/5787308/a7368f35567c/12879_2018_2963_Fig2_HTML.jpg

相似文献

1
The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV): facts, experiences and lessons learned from the south-south zone; Nigeria, April 2016.全球从三价口服脊髓灰质炎疫苗(tOPV)向二价口服脊髓灰质炎疫苗(bOPV)的转换:来自南南区域(尼日利亚)的事实、经验与教训,2016年4月
BMC Infect Dis. 2018 Jan 27;18(1):57. doi: 10.1186/s12879-018-2963-6.
2
Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.实施从三价口服脊髓灰质炎疫苗到二价口服脊髓灰质炎疫苗的同步全球转换——全球视角下的经验教训
J Infect Dis. 2017 Jul 1;216(suppl_1):S183-S192. doi: 10.1093/infdis/jiw626.
3
Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.2013 - 2016年全球灭活脊髓灰质炎疫苗的引入及三价口服脊髓灰质炎疫苗向二价口服脊髓灰质炎疫苗的转换
MMWR Morb Mortal Wkly Rep. 2015 Jul 3;64(25):699-702.
4
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.全球2型口服脊髓灰质炎疫苗同步停用的实施:意外使用三价口服脊髓灰质炎疫苗的风险
BMC Infect Dis. 2016 Jun 1;16:237. doi: 10.1186/s12879-016-1537-8.
5
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.通过比较中国不同脊髓灰质炎疫苗接种程序评估1型和3型口服脊髓灰质炎二价疫苗的免疫原性和安全性:一项随机对照非劣效性临床试验
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-10. doi: 10.1080/21645515.2017.1288769. Epub 2017 Mar 1.
6
Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.新常规疫苗接种计划在全球预防脊髓灰质炎中的免疫原性:一项开放标签、随机对照试验。
Lancet. 2015 Dec 12;386(10011):2413-21. doi: 10.1016/S0140-6736(15)00237-8. Epub 2015 Sep 18.
7
Mobilizing political support proved critical to a successful switch from tOPV to bOPV in Kano, Nigeria 2016.在 2016 年尼日利亚卡诺州,从口服脊髓灰质炎疫苗(tOPV)成功切换到 bOPV,争取政治支持被证明是至关重要的。
BMC Public Health. 2018 Dec 13;18(Suppl 4):1302. doi: 10.1186/s12889-018-6195-x.
8
India's Preparedness for Introduction of IPV and Switch from tOPV to bOPV.印度引入脊灰灭活疫苗以及从口服脊灰减毒活疫苗(tOPV)转换为二价口服脊灰减毒活疫苗(bOPV)的准备情况。
Indian Pediatr. 2016 Aug 7;53 Suppl 1:S44-S49.
9
Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.孟加拉国停止使用三价口服脊髓灰质炎疫苗后2型脊髓灰质炎病毒的社区传播:一项开放标签整群随机试验及模型研究
Lancet Infect Dis. 2017 Oct;17(10):1069-1079. doi: 10.1016/S1473-3099(17)30358-4. Epub 2017 Jul 7.
10
Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine-Lessons Learned.向符合条件的国家提供财政支持以从三价口服脊髓灰质炎疫苗转换为二价口服脊髓灰质炎疫苗——经验教训
J Infect Dis. 2017 Jul 1;216(suppl_1):S57-S65. doi: 10.1093/infdis/jiw577.

引用本文的文献

1
Poliomyelitis in Nigeria: Impact of Vaccination Services and Polio Intervention and Eradication Efforts.尼日利亚的脊髓灰质炎:疫苗接种服务以及脊髓灰质炎干预与根除工作的影响
Vaccines (Basel). 2025 Feb 25;13(3):232. doi: 10.3390/vaccines13030232.
2
Poliovirus Immunity among Children Aged 6-11 and 36-48 Months in 14 Polio High-Risk Provinces of Afghanistan: A Health-Facility-Based Study.阿富汗14个脊髓灰质炎高风险省份6至11岁及36至48个月儿童的脊髓灰质炎免疫力:一项基于医疗机构的研究
Vaccines (Basel). 2022 Oct 16;10(10):1726. doi: 10.3390/vaccines10101726.

本文引用的文献

1
Continued Endemic Wild Poliovirus Transmission in Security-Compromised Areas - Nigeria, 2016.2016年尼日利亚安全受影响地区野生脊灰病毒持续地方性传播
MMWR Morb Mortal Wkly Rep. 2017 Feb 24;66(7):190-193. doi: 10.15585/mmwr.mm6607a2.
2
Progress Toward Poliomyelitis Eradication - Pakistan, January 2015-September 2016.迈向消灭脊髓灰质炎的进展 - 巴基斯坦,2015 年 1 月至 2016 年 9 月。
MMWR Morb Mortal Wkly Rep. 2016 Nov 25;65(46):1295-1299. doi: 10.15585/mmwr.mm6546a4.
3
Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
三价口服脊髓灰质炎疫苗停用和灭活脊髓灰质炎疫苗引入-全球,2016 年。
MMWR Morb Mortal Wkly Rep. 2016 Sep 9;65(35):934-8. doi: 10.15585/mmwr.mm6535a3.
4
Profiling the immunity status of children with non-polio acute flaccid paralysis who had not received any doses of oral polio vaccine in the South-South region, Nigeria 2011-2014.剖析2011 - 2014年尼日利亚南南地区未接种任何口服脊髓灰质炎疫苗的非脊髓灰质炎急性弛缓性麻痹儿童的免疫状况。
Public Health. 2016 Oct;139:148-153. doi: 10.1016/j.puhe.2016.05.009. Epub 2016 Jun 11.
5
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.全球2型口服脊髓灰质炎疫苗同步停用的实施:潜在不同步停用的风险
BMC Infect Dis. 2016 May 26;16:231. doi: 10.1186/s12879-016-1536-9.
6
The Role of the Polio Program Infrastructure in Response to Ebola Virus Disease Outbreak in Nigeria 2014.脊髓灰质炎项目基础设施在尼日利亚应对2014年埃博拉病毒病疫情中的作用
J Infect Dis. 2016 May 1;213 Suppl 3(Suppl 3):S140-6. doi: 10.1093/infdis/jiv581. Epub 2016 Feb 16.
7
Polio endgame: the global switch from tOPV to bOPV.脊髓灰质炎收官之战:全球从口服脊灰减毒活疫苗(tOPV)向口服二价脊灰减毒活疫苗(bOPV)的转换
Expert Rev Vaccines. 2016 Jun;15(6):693-708. doi: 10.1586/14760584.2016.1140041. Epub 2016 Feb 2.
8
Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.在消灭脊髓灰质炎的最后阶段管理循环疫苗衍生脊髓灰质炎病毒的风险:口服脊髓灰质炎疫苗的需求
BMC Infect Dis. 2015 Sep 24;15:390. doi: 10.1186/s12879-015-1114-6.
9
Has Wild Poliovirus Been Eliminated from Nigeria?野生脊髓灰质炎病毒是否已在尼日利亚被消灭?
PLoS One. 2015 Aug 28;10(8):e0135765. doi: 10.1371/journal.pone.0135765. eCollection 2015.
10
Modeling the dynamics of oral poliovirus vaccine cessation.建模口服脊髓灰质炎疫苗停用的动力学。
J Infect Dis. 2014 Nov 1;210 Suppl 1:S475-84. doi: 10.1093/infdis/jit845.